Alprostadil

Alprostadil is a synthetic form of prostaglandin E1 used in regulated medicine primarily for erectile dysfunction, and in other product forms or regions for selected vascular indications. In a peptide-focused repository it fits best as a peptide-adjacent comparator because it is a well-characterized bioactive signal molecule rather than a peptide. This entry should be treated as a mature approved-drug benchmark rather than an exploratory wellness compound.

Common names include alprostadil and prostaglandin E1 analog references. Key marketed names include CAVERJECT for intracavernosal injection and historically MUSE for intraurethral administration. It is a small-molecule eicosanoid drug, not a peptide. Database tags should therefore mark it as peptide-adjacent, approved drug, erectile-dysfunction therapy, and prostaglandin-pathway agent.

Alprostadil acts as a prostaglandin receptor agonist that promotes smooth-muscle relaxation and vasodilation through cyclic-AMP signaling. In erectile-dysfunction use, direct local delivery to erectile tissue increases cavernosal arterial inflow and facilitates erection. The mechanism is pharmacologically clear and clinically validated, which makes alprostadil useful as a reference entry when comparing speculative compounds against an approved local-acting vasoactive therapy.

Best-established use is erectile dysfunction, including supervised dose titration and, for some products, diagnostic support in erectile-dysfunction workups. Depending on jurisdiction and formulation, alprostadil has also been used in neonatal ductus arteriosus management, but that is product-specific and should not be conflated with the sexual-medicine products most users mean by the name. In this repository, the primary use-case label should be regulated ED therapy.

For intracavernosal use, systemic exposure is low relative to the local pharmacodynamic effect. Available prescribing information notes extensive plasma protein binding, rapid metabolism with major first-pass pulmonary clearance after systemic entry, and urinary excretion of metabolites. Product-specific PK differs by route: direct penile injection is chiefly a local-delivery system, while intraurethral administration shows rapid absorption with short-lived systemic levels.

Evidence for erectile-dysfunction treatment is strong relative to most compounds in this repository because approved products were supported by controlled clinical development and long clinical use. Alprostadil is not necessarily first-line in modern practice because of convenience and tolerability tradeoffs versus oral PDE5 inhibitors, but it remains an effective established option when oral therapy is not suitable or not sufficient.

The main risks are product- and route-specific: penile pain, urethral discomfort or bleeding for urethral systems, hypotension or dizziness in some patients, prolonged erection, and priapism. Contraindication and caution screens matter, especially in people with conditions predisposing to prolonged erections or with penile structural abnormalities. Because the route is invasive and technique sensitive, safety depends heavily on proper medical instruction.

This database should not present a casual one-size-fits-all dose because alprostadil products are titrated and route dependent. Intracavernosal products are usually initiated under clinical supervision with individualized dose adjustment. Historical intraurethral products also required technique training and practical use counseling. Store exact regimen details at the product level rather than the generic-compound level.

The following dosing information has been compiled from community forums, researcher discussions, and gray-market sources. This information has NOT been verified through peer-reviewed scientific studies or clinical trials. It does NOT constitute medical advice, a prescription, or a recommendation for human use.

This data is presented solely for informational and educational purposes to document what is commonly discussed in research communities. Dosing protocols may be inaccurate, dangerous, or based on anecdotal reports with no scientific validation. Individual responses vary significantly, and unregulated compounds carry inherent risks including contamination, mislabeling, and unknown side effects.

Always consult qualified medical professionals before making any health-related decisions. The repository maintainers assume no liability for the use or misuse of this information.

Researcher-Reported Dosing Protocols

Common Dose Range: 1.25-60 mcg per injection

Administration Route: Intracavernosal injection or intraurethral suppository

Frequency: No more than 3 times per week

Timing: As needed before sexual activity

Schedule / Protocol: As needed for erectile dysfunction, not on a fixed cycle.

Dose Escalation: Start with a low dose (1.25-2.5 mcg) and titrate up by 2.5-10 mcg per injection until the desired effect is achieved. The lowest effective dose should always be used.

Additional Notes: Alprostadil is a vasodilator used for erectile dysfunction. It is also available in a more potent combination therapy called Trimix (alprostadil, papaverine, and phentolamine). Priapism (a prolonged erection) is a potential side effect that requires immediate medical attention.

This researcher-reported dosing information was compiled from unverified community sources and does not represent validated scientific or medical guidance.

This is a mature therapeutic area rather than an early exploratory one. Clinical evidence comes from historical registration programs and post-approval experience more than from a currently expanding development pipeline. If the repository later branches by product, separate trial records should be built for CAVERJECT, MUSE, and any non-U.S. vascular indications rather than pooling all route-specific evidence into one record.

Approved medicine, but status is formulation and jurisdiction specific. CAVERJECT remains an FDA-approved prescription drug for erectile dysfunction, while some older urethral-product availability has changed over time. For repository purposes, classify alprostadil as approved / marketed, with route-specific product records encouraged.

This entry is formulation sensitive. Intracavernosal products are supplied as sterile powders or solutions requiring careful preparation and administration, while urethral systems used a specialized suppository-applicator format. CMC and storage expectations are those of a conventional regulated sterile drug product rather than a research peptide vial.

Useful comparators include PT-141 for centrally mediated sexual-function signaling, VIP-based vasoactive concepts, and investigational erectile-tissue repair peptides. Alprostadil differs because it is an approved local pharmacologic vasodilator with a direct, established mechanism and real-world prescribing history.

Version 0.1 starter entry created March 15, 2026. Evidence basis for this draft: current CAVERJECT labeling and related official pharmacology materials.